WSCD2
gene geneOn this page
Also known as KIAA0789
Summary
WSCD2 (WSC domain sialate O sulfotransferase 2, HGNC:29117) is a protein-coding gene on chromosome 12q23.3, encoding Sialate:O-sulfotransferase 2 (Q2TBF2). Sialate:O-sulfotransferase which catalyzes 8-O-sulfation at the Sia-glycan level using 3’-phosphoadenosine 5’-phosphosulfate (PAPS) as a donor, forming 8-O-sulfated Sia (Sia8S)-glycans.
Predicted to enable sulfotransferase activity. Predicted to be located in Golgi membrane.
Source: NCBI Gene 9671 — RefSeq curated summary.
At a glance
- GWAS associations: 28
- Clinical variants (ClinVar): 98 total
- MANE Select transcript:
NM_014653
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:29117 |
| Approved symbol | WSCD2 |
| Name | WSC domain sialate O sulfotransferase 2 |
| Location | 12q23.3 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | KIAA0789 |
| Ensembl gene | ENSG00000075035 |
| Ensembl biotype | protein_coding |
| OMIM | 619253 |
| Entrez | 9671 |
Gene structure
Transcript identifiers
Ensembl transcripts: 16 — 8 protein_coding_CDS_not_defined, 7 protein_coding, 1 retained_intron
ENST00000332082, ENST00000546401, ENST00000546629, ENST00000546811, ENST00000547185, ENST00000547525, ENST00000549903, ENST00000550529, ENST00000551057, ENST00000551106, ENST00000551638, ENST00000551734, ENST00000552195, ENST00000854237, ENST00000854238, ENST00000854239
RefSeq mRNA: 2 — MANE Select: NM_014653
NM_001304447, NM_014653
CCDS: CCDS41828
Canonical transcript exons
ENST00000547525 — 9 exons
| Exon | Start | End |
|---|---|---|
| ENSE00000938221 | 108240344 | 108240544 |
| ENSE00001669802 | 108224739 | 108224860 |
| ENSE00001722460 | 108210121 | 108210305 |
| ENSE00001766844 | 108232731 | 108232895 |
| ENSE00001774185 | 108195282 | 108196214 |
| ENSE00002341368 | 108247991 | 108250537 |
| ENSE00002343185 | 108129288 | 108129926 |
| ENSE00003541687 | 108226990 | 108227164 |
| ENSE00003584280 | 108206289 | 108206403 |
Expression profiles
Bgee: expression breadth ubiquitous, 177 present calls, max score 97.41.
FANTOM5 (CAGE): breadth broad, TPM avg 1.9190 / max 217.5672, expressed in 372 samples.
FANTOM5 promoters (11 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 127867 | 0.6157 | 162 |
| 127870 | 0.2908 | 108 |
| 127871 | 0.1943 | 76 |
| 127873 | 0.1767 | 86 |
| 127875 | 0.1465 | 64 |
| 127868 | 0.1398 | 64 |
| 127869 | 0.1243 | 43 |
| 127865 | 0.1185 | 54 |
| 127874 | 0.0445 | 32 |
| 127866 | 0.0440 | 22 |
Top tissues by expression
245 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| cerebellar cortex | UBERON:0002129 | 97.41 | gold quality |
| cerebellar hemisphere | UBERON:0002245 | 97.38 | gold quality |
| cerebellum | UBERON:0002037 | 97.28 | gold quality |
| right hemisphere of cerebellum | UBERON:0014890 | 97.20 | gold quality |
| cerebellar vermis | UBERON:0004720 | 96.60 | gold quality |
| middle temporal gyrus | UBERON:0002771 | 93.17 | gold quality |
| tibia | UBERON:0000979 | 91.08 | gold quality |
| islet of Langerhans | UBERON:0000006 | 89.21 | gold quality |
| Brodmann (1909) area 23 | UBERON:0013554 | 88.89 | gold quality |
| primary visual cortex | UBERON:0002436 | 87.90 | gold quality |
| right lobe of thyroid gland | UBERON:0001119 | 87.25 | gold quality |
| calcaneal tendon | UBERON:0003701 | 87.06 | gold quality |
| thyroid gland | UBERON:0002046 | 86.96 | gold quality |
| left lobe of thyroid gland | UBERON:0001120 | 86.76 | gold quality |
| lower esophagus muscularis layer | UBERON:0035833 | 85.94 | gold quality |
| lower esophagus | UBERON:0013473 | 85.82 | gold quality |
| mucosa of stomach | UBERON:0001199 | 85.26 | gold quality |
| prefrontal cortex | UBERON:0000451 | 85.03 | gold quality |
| right frontal lobe | UBERON:0002810 | 85.02 | gold quality |
| cartilage tissue | UBERON:0002418 | 84.56 | gold quality |
| frontal cortex | UBERON:0001870 | 84.34 | gold quality |
| nucleus accumbens | UBERON:0001882 | 84.06 | gold quality |
| entorhinal cortex | UBERON:0002728 | 84.06 | gold quality |
| occipital lobe | UBERON:0002021 | 83.80 | gold quality |
| superior frontal gyrus | UBERON:0002661 | 83.42 | gold quality |
| dorsolateral prefrontal cortex | UBERON:0009834 | 83.04 | gold quality |
| Brodmann (1909) area 9 | UBERON:0013540 | 82.98 | gold quality |
| Brodmann (1909) area 46 | UBERON:0006483 | 82.95 | gold quality |
| neocortex | UBERON:0001950 | 82.77 | gold quality |
| postcentral gyrus | UBERON:0002581 | 82.59 | gold quality |
Single-cell (SCXA)
Detected in 3 experiment(s), a significant marker in 2.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-MTAB-5061 | yes | 18.48 |
| E-GEOD-83139 | yes | 10.02 |
| E-ANND-3 | no | 4.86 |
Regulation
Is transcription factor: no
Upstream regulators (CollecTRI, top): NR1I2
miRNA regulators (miRDB)
92 targeting WSCD2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-7110-3P | 100.00 | 73.18 | 2486 |
| HSA-MIR-8485 | 100.00 | 77.57 | 4731 |
| HSA-MIR-6873-3P | 100.00 | 71.42 | 2626 |
| HSA-MIR-6758-5P | 100.00 | 66.21 | 1470 |
| HSA-MIR-6856-5P | 100.00 | 65.47 | 1298 |
| HSA-MIR-4481 | 100.00 | 66.42 | 1669 |
| HSA-MIR-5193 | 100.00 | 67.26 | 1744 |
| HSA-MIR-4262 | 100.00 | 73.26 | 3931 |
| HSA-MIR-4745-5P | 99.98 | 65.95 | 1028 |
| HSA-MIR-548AN | 99.97 | 70.91 | 2817 |
| HSA-MIR-6888-3P | 99.97 | 65.95 | 1170 |
| HSA-MIR-4725-3P | 99.96 | 69.53 | 2520 |
| HSA-MIR-6780B-5P | 99.96 | 69.60 | 2562 |
| HSA-MIR-2110 | 99.96 | 66.68 | 1930 |
| HSA-MIR-3119 | 99.92 | 71.34 | 2390 |
| HSA-MIR-6499-3P | 99.90 | 66.38 | 1212 |
| HSA-MIR-4493 | 99.90 | 66.48 | 977 |
| HSA-MIR-605-3P | 99.88 | 69.22 | 1833 |
| HSA-MIR-4271 | 99.88 | 68.32 | 2244 |
| HSA-MIR-3941 | 99.86 | 70.54 | 2735 |
| HSA-MIR-4447 | 99.85 | 67.81 | 2900 |
| HSA-MIR-6817-3P | 99.79 | 68.35 | 2126 |
| HSA-MIR-4713-5P | 99.78 | 67.80 | 1794 |
| HSA-MIR-6745 | 99.74 | 65.33 | 1321 |
| HSA-MIR-4524A-3P | 99.72 | 66.85 | 2406 |
| HSA-MIR-1296-3P | 99.72 | 64.04 | 636 |
| HSA-MIR-4306 | 99.72 | 70.50 | 3630 |
| HSA-MIR-3059-5P | 99.70 | 69.93 | 2491 |
| HSA-MIR-7154-5P | 99.69 | 70.52 | 1900 |
| HSA-MIR-1251-3P | 99.64 | 67.21 | 1408 |
Literature-anchored findings (GeneRIF, showing 1)
- WSCD2 polymorphism is associated with extraversion. (PMID:27918536)
Cross-species orthologs
22 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | wscd2 | ENSDARG00000061819 |
| mus_musculus | Wscd2 | ENSMUSG00000063430 |
| rattus_norvegicus | Wscd2 | ENSRNOG00000053045 |
| drosophila_melanogaster | oxt | FBGN0015360 |
| drosophila_melanogaster | CG9164 | FBGN0030634 |
| caenorhabditis_elegans | gly-15 | WBGENE00001640 |
| caenorhabditis_elegans | gly-16 | WBGENE00001641 |
| caenorhabditis_elegans | gly-17 | WBGENE00001642 |
| caenorhabditis_elegans | gly-18 | WBGENE00001643 |
| caenorhabditis_elegans | gly-19 | WBGENE00001644 |
| caenorhabditis_elegans | WBGENE00005024 | |
| caenorhabditis_elegans | WBGENE00009148 | |
| caenorhabditis_elegans | F30A10.4 | WBGENE00009263 |
| caenorhabditis_elegans | WBGENE00011090 | |
| caenorhabditis_elegans | T09E11.6 | WBGENE00011655 |
| caenorhabditis_elegans | T09E11.9 | WBGENE00011658 |
| caenorhabditis_elegans | T27F6.1 | WBGENE00012102 |
| caenorhabditis_elegans | WBGENE00012135 | |
| caenorhabditis_elegans | WBGENE00013119 | |
| caenorhabditis_elegans | ZK1225.2 | WBGENE00014236 |
| caenorhabditis_elegans | WBGENE00019270 | |
| caenorhabditis_elegans | WBGENE00019919 |
Paralogs (8): XYLT2 (ENSG00000015532), XYLT1 (ENSG00000103489), GCNT2 (ENSG00000111846), GCNT7 (ENSG00000124091), GCNT3 (ENSG00000140297), GCNT4 (ENSG00000176928), WSCD1 (ENSG00000179314), GCNT1 (ENSG00000187210)
Protein
Protein identifiers
Sialate:O-sulfotransferase 2 — Q2TBF2 (reviewed: Q2TBF2)
Alternative names: WSC domain-containing protein 2
All UniProt accessions (2): Q2TBF2, F8W030
UniProt curated annotations — full annotation on UniProt →
Function. Sialate:O-sulfotransferase which catalyzes 8-O-sulfation at the Sia-glycan level using 3’-phosphoadenosine 5’-phosphosulfate (PAPS) as a donor, forming 8-O-sulfated Sia (Sia8S)-glycans. Displays selectivity toward glycoproteins such as TF/transferrin.
Subcellular location. Golgi apparatus membrane.
Similarity. Belongs to the WSCD family.
Isoforms (2)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q2TBF2-1 | 1 | yes |
| Q2TBF2-2 | 2 |
RefSeq proteins (2): NP_001291376, NP_055468* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR002889 | WSC_carb-bd | Domain |
| IPR027417 | P-loop_NTPase | Homologous_superfamily |
| IPR051589 | Sialate-O-sulfotransferase | Family |
Pfam: PF01822
UniProt features (12 total): topological domain 2, sequence conflict 2, domain 2, glycosylation site 2, chain 1, transmembrane region 1, splice variant 1, sequence variant 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q2TBF2-F1 | 79.00 | 0.50 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Glycosylation sites (2): 189, 242
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 0 (showing top):
GO Biological Process (0):
GO Molecular Function (1): sulfotransferase activity (GO:0008146)
GO Cellular Component (3): Golgi membrane (GO:0000139), Golgi apparatus (GO:0005794), membrane (GO:0016020)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| transferase activity, transferring sulphur-containing groups | 1 |
| Golgi apparatus | 1 |
| bounding membrane of organelle | 1 |
| cytoplasm | 1 |
| endomembrane system | 1 |
| intracellular membrane-bounded organelle | 1 |
| cellular anatomical structure | 1 |
Protein interactions and networks
STRING
1416 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| WSCD2 | SPATA31A6 | Q5VVP1 | 435 |
| WSCD2 | SGSM1 | Q2NKQ1 | 434 |
| WSCD2 | ZNF771 | Q7L3S4 | 397 |
| WSCD2 | CFAP107 | Q8N1D5 | 395 |
| WSCD2 | QSER1 | Q2KHR3 | 392 |
| WSCD2 | LRP2BP | Q9P2M1 | 388 |
| WSCD2 | EFCAB12 | Q6NXP0 | 386 |
| WSCD2 | LURAP1L | Q8IV03 | 380 |
| WSCD2 | RGS22 | Q8NE09 | 362 |
| WSCD2 | ANKH | Q9HCJ1 | 352 |
| WSCD2 | DCAF8L2 | P0C7V8 | 351 |
| WSCD2 | SPATA31D1 | Q6ZQQ2 | 346 |
| WSCD2 | POC5 | Q8NA72 | 340 |
| WSCD2 | FRMD7 | Q6ZUT3 | 339 |
| WSCD2 | SCD5 | Q86SK9 | 327 |
IntAct
0 interactions, top by confidence:
BioGRID (1): WSCD2 (Cross-Linking-MS (XL-MS))
ESM2 similar proteins: A0A8C2LVE3, A2BGL3, F4HXW9, O08889, O17645, O43909, O43916, O93336, O93403, O95461, P25722, P69478, P79948, Q0IIY2, Q2TBF2, Q5NDE4, Q5NDE5, Q5NDE6, Q5NDE7, Q5NDE8, Q5NVB3, Q5R621, Q5RJQ0, Q5XHM7, Q66PG1, Q66PG2, Q66PG3, Q6DBY9, Q6NVP8, Q6P9A2, Q6PA90, Q76EC5, Q76KB1, Q7LFX5, Q7LGA3, Q7LGC8, Q7T3S3, Q800H9, Q8BUB6, Q8CHI9
Diamond homologs: A2BGL3, D4PHA7, P54867, P84675, Q0IIY2, Q16WU7, Q29G54, Q2TBF2, Q505J3, Q5QQ52, Q5QQ53, Q658N2, Q7KVA1, Q7Q297, Q80XH4, Q8K1S7, Q965Q8, Q9VXV9, Q8NCW0, D4AUF1, D4AUF4, Q90Y90, Q924S4, Q96MU8, Q99N43, Q5QQ49, Q5QQ50, Q5QQ51, Q5QQ54, Q5QQ55, Q5QQ56, Q5QQ57, Q811B1, Q86Y38, Q9EPI0, Q9EPI1, Q9EPL0, Q9H1B5
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
98 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 90 |
| Likely benign | 1 |
| Benign | 2 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
2497 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 12:108129924:CAG:C | donor_loss | 1.0000 |
| 12:108129925:AG:A | donor_loss | 1.0000 |
| 12:108129926:GGTAA:G | donor_loss | 1.0000 |
| 12:108129927:GT:G | donor_loss | 1.0000 |
| 12:108224728:T:TA | acceptor_gain | 1.0000 |
| 12:108224735:TCA:T | acceptor_loss | 1.0000 |
| 12:108224736:CA:C | acceptor_loss | 1.0000 |
| 12:108224737:A:AG | acceptor_gain | 1.0000 |
| 12:108224737:AGAT:A | acceptor_gain | 1.0000 |
| 12:108224738:G:GG | acceptor_gain | 1.0000 |
| 12:108224738:GAT:G | acceptor_gain | 1.0000 |
| 12:108224738:GATG:G | acceptor_gain | 1.0000 |
| 12:108224857:GAAG:G | donor_gain | 1.0000 |
| 12:108224859:AGGTG:A | donor_loss | 1.0000 |
| 12:108224860:GG:G | donor_loss | 1.0000 |
| 12:108224862:T:A | donor_loss | 1.0000 |
| 12:108232893:AAGG:A | donor_loss | 1.0000 |
| 12:108232894:AGGT:A | donor_loss | 1.0000 |
| 12:108232896:G:GA | donor_loss | 1.0000 |
| 12:108232897:T:A | donor_loss | 1.0000 |
| 12:108247986:T:TA | acceptor_gain | 1.0000 |
| 12:108247986:TGCAG:T | acceptor_gain | 1.0000 |
| 12:108247988:CA:C | acceptor_loss | 1.0000 |
| 12:108247988:CAG:C | acceptor_gain | 1.0000 |
| 12:108247989:A:AC | acceptor_loss | 1.0000 |
| 12:108247989:A:AG | acceptor_gain | 1.0000 |
| 12:108247989:AGA:A | acceptor_gain | 1.0000 |
| 12:108247989:AGAGT:A | acceptor_gain | 1.0000 |
| 12:108247990:G:GT | acceptor_gain | 1.0000 |
| 12:108247990:GA:G | acceptor_gain | 1.0000 |
AlphaMissense
3714 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 12:108232793:A:C | S348R | 1.000 |
| 12:108232795:C:A | S348R | 1.000 |
| 12:108232795:C:G | S348R | 1.000 |
| 12:108232813:C:A | N354K | 1.000 |
| 12:108232813:C:G | N354K | 1.000 |
| 12:108240396:G:C | K399N | 1.000 |
| 12:108240396:G:T | K399N | 1.000 |
| 12:108240402:C:A | H401Q | 1.000 |
| 12:108240402:C:G | H401Q | 1.000 |
| 12:108240484:T:C | F429L | 1.000 |
| 12:108240486:C:A | F429L | 1.000 |
| 12:108240486:C:G | F429L | 1.000 |
| 12:108240490:C:A | R431S | 1.000 |
| 12:108240491:G:C | R431P | 1.000 |
| 12:108247993:T:A | W450R | 1.000 |
| 12:108247993:T:C | W450R | 1.000 |
| 12:108247995:G:C | W450C | 1.000 |
| 12:108247995:G:T | W450C | 1.000 |
| 12:108248002:T:C | F453L | 1.000 |
| 12:108248004:C:A | F453L | 1.000 |
| 12:108248004:C:G | F453L | 1.000 |
| 12:108206303:T:A | C133S | 0.999 |
| 12:108206303:T:C | C133R | 0.999 |
| 12:108206304:G:C | C133S | 0.999 |
| 12:108206306:T:G | Y134D | 0.999 |
| 12:108206381:T:A | C159S | 0.999 |
| 12:108206381:T:C | C159R | 0.999 |
| 12:108206382:G:C | C159S | 0.999 |
| 12:108206393:T:A | C163S | 0.999 |
| 12:108206393:T:C | C163R | 0.999 |
dbSNP variants (sampled 300 via entrez): RS1000001833 (12:108205359 A>G), RS1000008605 (12:108247481 G>A,C,T), RS1000012321 (12:108132680 C>T), RS1000080930 (12:108176968 G>C), RS1000098806 (12:108211674 G>A), RS1000124017 (12:108220174 T>A,C), RS1000157544 (12:108138490 G>A,T), RS1000184132 (12:108230242 T>G), RS1000192136 (12:108245589 C>T), RS1000264165 (12:108144630 G>A), RS1000272642 (12:108150262 C>G), RS1000286789 (12:108175509 A>G), RS1000339699 (12:108163330 C>T), RS1000353153 (12:108132405 T>A), RS1000358634 (12:108206797 TGTAG>T)
Disease associations
OMIM: gene MIM:619253 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
28 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST001419_5 | Temperament (bipolar disorder) | 8.000000e-06 |
| GCST002481_2 | Acne (severe) | 5.000000e-06 |
| GCST004015_4 | Extraversion | 1.000000e-14 |
| GCST007325_288 | General risk tolerance (MTAG) | 2.000000e-17 |
| GCST007483_3 | Waist-to-hip ratio adjusted for BMI (additive genetic model) | 1.000000e-09 |
| GCST007487_54 | Waist-to-hip ratio adjusted for BMI (additive genetic model) | 9.000000e-09 |
| GCST007492_16 | Waist-to-hip ratio adjusted for BMI (additive genetic model) | 9.000000e-07 |
| GCST007494_12 | Waist-to-hip ratio adjusted for BMI (additive genetic model) | 8.000000e-06 |
| GCST007515_37 | Type 2 diabetes | 3.000000e-08 |
| GCST007516_27 | Type 2 diabetes (adjusted for BMI) | 1.000000e-07 |
| GCST007517_19 | Type 2 diabetes | 9.000000e-08 |
| GCST007518_25 | Type 2 diabetes (adjusted for BMI) | 6.000000e-08 |
| GCST007561_70 | Sleep duration | 3.000000e-08 |
| GCST007710_17 | Anxiety/tension (special factor of neuroticism) | 2.000000e-10 |
| GCST007847_116 | Type 2 diabetes | 1.000000e-08 |
| GCST008103_157 | Bipolar disorder | 6.000000e-06 |
| GCST009312_10 | Antisaccade task score | 2.000000e-06 |
| GCST009379_344 | Type 2 diabetes | 8.000000e-12 |
| GCST010118_84 | Type 2 diabetes | 8.000000e-12 |
| GCST010926_2 | Waist-to-hip ratio adjusted for BMI | 5.000000e-11 |
| GCST010988_501 | Adult body size | 2.000000e-14 |
| GCST90000025_995 | Appendicular lean mass | 4.000000e-39 |
| GCST90000026_38 | Appendicular lean mass | 7.000000e-19 |
| GCST90000027_18 | Appendicular lean mass | 1.000000e-23 |
| GCST90020024_236 | A body shape index | 8.000000e-11 |
| GCST90020025_102 | Waist-to-hip ratio adjusted for BMI | 5.000000e-09 |
| GCST90020027_1681 | Waist-hip index | 6.000000e-09 |
| GCST90020029_465 | Waist circumference adjusted for body mass index | 6.000000e-09 |
EFO canonical traits (8, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0004365 | personality trait |
| EFO:0004317 | extraversion |
| EFO:0008579 | risk-taking behaviour |
| EFO:0007788 | BMI-adjusted waist-hip ratio |
| EFO:0009863 | anxiety measurement |
| EFO:0007969 | cognitive inhibition measurement |
| EFO:0004980 | appendicular lean mass |
| EFO:0007789 | BMI-adjusted waist circumference |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
14 total (human), top 14 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Valproic Acid | affects expression, increases expression | 3 |
| Phenylmercuric Acetate | affects cotreatment, decreases expression | 2 |
| S-(1,2-dichlorovinyl)cysteine | affects response to substance, increases expression, affects cotreatment, decreases expression | 1 |
| 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | decreases expression, affects cotreatment | 1 |
| dorsomorphin | affects cotreatment, decreases expression | 1 |
| Benzo(a)pyrene | affects methylation, increases methylation | 1 |
| Carbamazepine | affects expression | 1 |
| Doxorubicin | increases expression | 1 |
| Folic Acid | decreases expression | 1 |
| Lipopolysaccharides | increases expression, affects cotreatment, decreases expression, affects response to substance | 1 |
| Tobacco Smoke Pollution | decreases expression | 1 |
| Triclosan | decreases expression | 1 |
| Aflatoxin B1 | decreases methylation | 1 |
| Antirheumatic Agents | increases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.